Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Relief
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VNDA?
Source: PRnewswire
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication for motion sickness in over 40 years, addressing the urgent need of 65 to 78 million American adults for new treatment options.
- Innovative Direct-to-Consumer Platform: NEREUS™ is available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, significantly lower than the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: The drug demonstrated significant efficacy in two pivotal Phase 3 clinical trials, effectively preventing vomiting compared to placebo, confirming its effectiveness in real-world sea travel conditions and marking a major breakthrough in motion sickness treatment.
- Historical Significance: The launch of NEREUS™ not only provides a new treatment option for millions suffering from motion sickness but also has the potential to transform future travel experiences by reducing the impact of motion sickness on military and exploratory activities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.100
Low
7.50
Averages
13.63
High
22.00
Current: 7.100
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda Pharmaceuticals to Release Q1 2026 Results on May 6
- Earnings Release Announcement: Vanda Pharmaceuticals will release its Q1 2026 financial results on May 6, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call at 4:30 PM ET on the same day, during which management will discuss financial results and other corporate activities, aiming to enhance investor understanding of the company's strategy.
- Participation Details: Investors can dial 1-888-596-4144 for domestic calls or 1-646-968-2525 for international calls to participate, using passcode 8051722, ensuring smooth information dissemination.
- Replay Information: The call replay will be available starting at 8:30 PM ET on May 6, 2026, until May 13 at 11:59 PM, with domestic replay at 1-800-770-2030 and international at 1-609-800-9909, further enhancing investor accessibility.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Treatment
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication approved for motion sickness in over 40 years, which is expected to significantly improve the quality of life for tens of millions of patients.
- Direct-to-Consumer Access: NEREUS™ is now available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, a significant discount from the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: NEREUS™ demonstrated significant efficacy in preventing vomiting in two pivotal Phase 3 clinical trials conducted under real-world conditions, confirming its effectiveness for patients experiencing motion sickness during actual sea travel, thus providing a new treatment option.
- Historical Significance: The launch of NEREUS™ addresses a long-standing lack of effective treatments for motion sickness and may have positive implications for military and aerospace sectors, enhancing human adaptability in various motion environments.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Relief
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication for motion sickness in over 40 years, addressing the urgent need of 65 to 78 million American adults for new treatment options.
- Innovative Direct-to-Consumer Platform: NEREUS™ is available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, significantly lower than the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: The drug demonstrated significant efficacy in two pivotal Phase 3 clinical trials, effectively preventing vomiting compared to placebo, confirming its effectiveness in real-world sea travel conditions and marking a major breakthrough in motion sickness treatment.
- Historical Significance: The launch of NEREUS™ not only provides a new treatment option for millions suffering from motion sickness but also has the potential to transform future travel experiences by reducing the impact of motion sickness on military and exploratory activities.
See More
Vanda Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Vanda Pharmaceuticals is set to announce its Q1 2026 financial results on May 6, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call at 4:30 PM ET on the same day, during which management will discuss financial results and other corporate activities, aiming to enhance investor understanding of the company's operations.
- Participation Details: Investors can join the call by dialing 1-888-596-4144 for domestic or 1-646-968-2525 for international participants, using passcode 8051722, ensuring smooth information dissemination.
- Replay Information: A replay of the call will be available starting at 8:30 PM ET on May 6, 2026, until May 13, providing access for those unable to attend live, further enhancing the company's engagement with investors.
See More
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
See More
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical trials that is expected to enhance market recognition.
- BLA Submission: Vanda has submitted a Biologics License Application for Imsidolimab to the FDA, with a target action date of December 12, 2026, which could expedite the drug's market entry and address urgent patient needs.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is anticipated to extend into the late 2030s, providing Vanda with a long-term competitive advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only enhances the diversity of its product portfolio but also lays a foundation for future revenue growth.
See More
Vanda Pharmaceuticals to Release Q1 2026 Results on May 6
- Earnings Release Announcement: Vanda Pharmaceuticals will release its Q1 2026 financial results on May 6, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call at 4:30 PM ET on the same day, during which management will discuss financial results and other corporate activities, aiming to enhance investor understanding of the company's strategy.
- Participation Details: Investors can dial 1-888-596-4144 for domestic calls or 1-646-968-2525 for international calls to participate, using passcode 8051722, ensuring smooth information dissemination.
- Replay Information: The call replay will be available starting at 8:30 PM ET on May 6, 2026, until May 13 at 11:59 PM, with domestic replay at 1-800-770-2030 and international at 1-609-800-9909, further enhancing investor accessibility.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Treatment
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication approved for motion sickness in over 40 years, which is expected to significantly improve the quality of life for tens of millions of patients.
- Direct-to-Consumer Access: NEREUS™ is now available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, a significant discount from the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: NEREUS™ demonstrated significant efficacy in preventing vomiting in two pivotal Phase 3 clinical trials conducted under real-world conditions, confirming its effectiveness for patients experiencing motion sickness during actual sea travel, thus providing a new treatment option.
- Historical Significance: The launch of NEREUS™ addresses a long-standing lack of effective treatments for motion sickness and may have positive implications for military and aerospace sectors, enhancing human adaptability in various motion environments.
See More
Vanda Pharmaceuticals Launches NEREUS™ for Motion Sickness Relief
- First New Drug Launch: Vanda Pharmaceuticals announces the commercial availability of NEREUS™ (tradipitant) in the U.S., marking the first new prescription medication for motion sickness in over 40 years, addressing the urgent need of 65 to 78 million American adults for new treatment options.
- Innovative Direct-to-Consumer Platform: NEREUS™ is available through a new direct-to-consumer platform (nereus.us), allowing patients to purchase it at a cash price of $85 per dose, significantly lower than the standard price of $255, enhancing accessibility and convenience for patients.
- Successful Clinical Trials: The drug demonstrated significant efficacy in two pivotal Phase 3 clinical trials, effectively preventing vomiting compared to placebo, confirming its effectiveness in real-world sea travel conditions and marking a major breakthrough in motion sickness treatment.
- Historical Significance: The launch of NEREUS™ not only provides a new treatment option for millions suffering from motion sickness but also has the potential to transform future travel experiences by reducing the impact of motion sickness on military and exploratory activities.
See More
Vanda Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Vanda Pharmaceuticals is set to announce its Q1 2026 financial results on May 6, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will host a conference call at 4:30 PM ET on the same day, during which management will discuss financial results and other corporate activities, aiming to enhance investor understanding of the company's operations.
- Participation Details: Investors can join the call by dialing 1-888-596-4144 for domestic or 1-646-968-2525 for international participants, using passcode 8051722, ensuring smooth information dissemination.
- Replay Information: A replay of the call will be available starting at 8:30 PM ET on May 6, 2026, until May 13, providing access for those unable to attend live, further enhancing the company's engagement with investors.
See More
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
See More
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical trials that is expected to enhance market recognition.
- BLA Submission: Vanda has submitted a Biologics License Application for Imsidolimab to the FDA, with a target action date of December 12, 2026, which could expedite the drug's market entry and address urgent patient needs.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is anticipated to extend into the late 2030s, providing Vanda with a long-term competitive advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only enhances the diversity of its product portfolio but also lays a foundation for future revenue growth.
See More
